About ARDX

Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat gastrointestinal and cardio-renal diseases. Ardelyx has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, Ardelyx has discovered and designed tenapanor, which it is evaluating for the treatment of constipation-predominant irritable bowel syndrome, or IBS-C, and management of hyperphosphatemia in patients with end stage renal disease. In addition to tenapanor, Ardelyx is developing RDX022, a non-absorbed polymer for the treatment of hyperkalemia, or high potassium, in kidney and heart disease patients. Ardelyx is also advancing several research programs focused in gastrointestinal and cardio-renal diseases. Ardelyx is located in Fremont, California.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ARDX is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
URTY ProShares UltraPro Russell2000 88.4 M 8.8426E+07 1,997 1997 0.0% 1.18904E-05 4 K 3503
UWM ProShares Ultra Russell2000 156.9 M 1.56936E+08 1,997 1997 0.0% 2.30614E-05 8 K 7804
PXSV Invesco Russell 2000 Pure Value ETF 74.8 M 7.48E+07 316 316 0.03% 0.00033 24 K 24491
ITOT iShares Core S&P Total U.S. Stock Market ETF 20.5 B 2.05289E+10 3,545 3545 0.0% 0 34 K 33943
IWC iShares Microcap ETF 854.9 M 8.5486E+08 1,430 1430 0.03% 0.0003 274 K 273605
IWM iShares Russell 2000 ETF 41.1 B 4.11417E+10 1,985 1985 0.01% 0.0001 2.4 M 2382260
IWN iShares Russell 2000 Value ETF 8.6 B 8.5849E+09 1,351 1351 0.01% 0.0001 1.0 M 1017430
IWV iShares Russell 3000 ETF 9.3 B 9.30952E+09 2,929 2929 0.0% 0 22 K 21828